8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
Mar 3, 2026·SEC
Delcath Systems, Inc.(DCTH)Earnings, Financials & Key Ratios
DCTH•NASDAQ
$13.44
198.8× P/E·Price updated Jul 7, 2026
AboutDelcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.Show more
- Revenue$85M+129.1%
- EBITDA$1M+108.3%
- Net Income$3M+110.2%
- EPS (Diluted)0.07+107.3%
- Gross Margin86.16%+3.3%
- EBITDA Margin1.18%+103.6%
- Operating Margin0.77%+102.3%
- Net Margin3.17%+104.5%
- ROE3%+104.8%
DCTH Price & Volume
Delcath Systems, Inc. (DCTH) stock price & volume — 10-year historical chart
Loading chart...
Commercial Scaling Challenges Amidst Robust Gross Margins
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Accelerating
Profitability:Strained
Financial:Healthy
Cash Flow:Mixed
Primary Risk:Commercial adoption and execution
Key Thesis Takeaways
- Delcath Systems has successfully transitioned to a commercial-stage entity, evidenced by a 26.3% revenue growth rate in 2026Q1, though the company faces significant hurdles in achieving consistent operating profitability.
- While the 85.1% gross margin profile provides a strong foundation, the high-touch nature of the HEPZATO KIT rollout necessitates substantial SG&A investment that may continue to pressure operating income.
- Investors should monitor the sustainability of recent cash flow improvements and the company's ability to manage its $529.9M accumulated deficit while scaling its specialized interventional oncology infrastructure.
Verdict Logic
while the company has achieved a significant revenue trajectory shift, the ongoing reliance on external capital and the volatility in free cash flow, which peaked at $7.7M in 2025Q4, warrant further investigation into the long-term scalability of the commercial model.
DCTH Growth Metrics
Delcath Systems, Inc. (DCTH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years47.51%
5 Years120.21%
3 Years215.3%
TTM67.95%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM103.95%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM101.19%
Return on Capital
10 Years-2244.85%
5 Years-129.25%
3 Years-109.34%
Last Year0.72%
Peers Comparison
Key metrics vs top competitors for Delcath Systems, Inc. (DCTH)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $13.44 | $463.97M | 198.82 | 129.08% | 3.17% | 3% | — | |
| $17.72 | $2.02B | -14.52 | 8.28% | -25.66% | -50.82% | — | |
| $3.50 | $145.75M | -1029.41 | 10.37% | 52.16% | — | — | |
| $39.93 | $2.66B | -10.24 | -78.63% | -34596.22% | -50.72% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — | |
| $81.57 | $9.68B | 31.86 | 37.55% | 23.13% | 126.27% | — |
Compare DCTH vs Peers
Delcath Systems, Inc. (DCTH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
DCTH SEC Filings & Documents
Delcath Systems, Inc. (DCTH) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when DCTH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
DCTH Frequently Asked Questions
Delcath Systems, Inc. (DCTH) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Delcath Systems, Inc.'s revenue?
Delcath Systems, Inc. (DCTH) reported $90.4M in revenue for fiscal year 2025.
How fast is Delcath Systems, Inc. growing?
Delcath Systems, Inc. (DCTH) grew revenue by 129.1% over the past year. This is strong growth.
Is DCTH profitable?
Yes, Delcath Systems, Inc. (DCTH) is profitable, generating $0.6M in net income for fiscal year 2025 (3.2% net margin).
Dividend & Returns
What is DCTH's return on equity?
Delcath Systems, Inc. (DCTH) has a return on equity (ROE) of 3.0%. This is below average, suggesting room for improvement.
What is Delcath Systems, Inc.'s free cash flow?
Delcath Systems, Inc. (DCTH) generated $19.2M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.